Antibody based immunotherapy for multiple myeloma: It's about time

Leukemia and Lymphoma

Volumn 57, Issue 2, 2016, Pages 269-275

  Sher, Taimur ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

antibody therapy; CD38; immunotherapy; Myeloma; SLAMF7

Indexed keywords

ANTINEOPLASTIC AGENT; BHQ 880; DARATUMUMAB; DENOSUMAB; ELOTUZUMAB; FIGITUMUMAB; INDATUXIMAB RAVTANSINE; IPH 2101; ISATUXIMAB; LORVOTUZUMAB MERTANSINE; MDX 1097; MONOCLONAL ANTIBODY; PRO 001; SILTUXIMAB; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE DISEASE; CANCER IMMUNOTHERAPY; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT;

EID: 84955190395     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1092530     Document Type: Review

References (36)

1. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007; 138: 563-579.
2. Danylesko I, Beider K, Shimoni A, et al. Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol 2012; 2012: 753407.
3. Chillemi A, Zaccarello G, Quarona V, et al. CD38 and bone marrow microenvironment. Front Biosci (Landmark Ed) 2014; 19: 152-162.
4. Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs 2015; 7: 311-321.
5. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015; 373: 1207-1219
6. Lonial S, Weiss BM, Usmani SZ, et al. Phase II study of Daratumumab (DARA) monotherapy in patients with more than 3 lines of prior therapy or double refractory multiple myeloma. J Clin Oncol 2015; 33(Suppl):asbtract LBA8512.
7. Nijhof IS, van Bueren JJL, van Kessel B, et al. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica 2015; 100: 263-268.
8. Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38 + hematologic malignancies. Clin Cancer Res 2014; 20: 4574-4583.
9. Martin TG, Hsu K, Strickland SA, et al. A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma. J Clin Oncol 2014; 32:8532.
10. Martin TG, Baz R, Benson DM, et al. A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. Blood 2014; 124(21): Abstract 83.
11. Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol 2013; 88: 168-177.
12. Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunology, Immunotherapy 2013; 62: 1841-1849.
13. Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012; 120: 552-559.
14. Richardson PG, et al. Final results for the 1703 phase 1b/2 study of elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 2014; 124:(21): 302.
15. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015; 373: 621-631.
16. Terpos E, Kanellias N, Giannopoulos K. Biology and management of myeloma-related bone disease. Acta Haematol Polonica 2014; 45: 107-121.
17. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132.
18. Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009; 114: 371-379.
19. Padmanabhan S, Beck JT, Kelly KR, et al. A phase I/II study of BHQ880, a novel osteoblast activating, anti-DKK1 human monoclonal antibody, in relapsed and refractory multiple myeloma (MM) patients treated with zoledronic acid (Zol) and anti-myeloma therapy (MM Tx). Blood 2009; 114: 312-313.
20. Chang Q, Daly L, Bromberg J. The IL-6 feed-forward loop: a driver of tumorigenesis. Semin Immunol 2014; 26: 48-53.
21. Markham A, Patel T. Siltuximab: first global approval. Drugs 2014; 74: 1147-1152.
22. Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013; 19: 3659-3670.
23. Orlowski RZ, Gercheva L, Williiams C, et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol 2015; 90: 42-49.
24. San-Miguel J, Bladé J, Shpilberg O, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 2014; 123: 4136-4142.
25. Allegra A, Penna G, Alonci A, et al. Monoclonal antibodies: Potential new therapeutic treatment against multiple myeloma. Eur J Haematol 2013; 90: 441-468.
26. Scagliotti GV, Bondarenko I, Blackhall F, et al. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Ann Oncol 2015; 26: 497-504.
27. West H. The failure of figitumumab: the danger of taking shortcuts in drug development. Ann Oncol 2015; 26: 447-448.
28. Franklin R, Samson MK, Fraile RJ, et al. A phase I-II study of maytansine utilizing a weekly schedule. Cancer 1980; 46: 1104-1108.
29. Kim SU, Tomonaga M, Ghetti B. Neurofibrillary degeneration in cultured adult mouse neurons induced by maytansine. Acta Neuropathol 1980; 52: 161-164.
30. Ikeda H, Hideshima T, Fulciniti M, et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009; 15: 4028-4037.
31. Kelly KR, Chanan-Khan A, Heffner LT, et al. Indatuximab Ravtansine (BT062) in combination with Lenalidomide and low-dose Dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in patients already exposed to Lenalidomide and Bortezomib. Blood 2014; 124.
32. Chanan-Khan A, Wolf J, Garcia J, et al. Efficacy analysis from a Phase I Study of Lorvotuzumab Mertansine (IMGN901), used as Monotherapy, in patients with heavily pre-treated CD56-Positive Multiple Myeloma-A preliminary efficacy analysis. Blood 2010; 116: 819-819.
33. Berdeja JG. Lorvotuzumab mertansine: antibody-drug-conjugate for CD56 + multiple myeloma. Front Biosci (Landmark Ed) 2014; 19: 163-170.
34. Spencer A, Walker P, Asvadi P, et al. A phase I study of the anti-appa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients. J Clin Oncol 2010; 28: 8143.
35. Korde N, Carlsten M, Lee M-J, et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 2014; 99: e81-83.
36. Trudel S, Wei E, Hua Z, et al. Targeting FGFR3 in t(4;14) mutiple myeloma: pre-clinical studies of PRO-001, a novel anti-FGFR3 neutralizing antibody. Blood 2004; 104: 680A.